Drug intelligence / Profile preview

ONC-XXX

Development stage: Preclinical
Lead developer: OncoC4

Overview

ONC-XXX is a placeholder designation for an early-stage preclinical drug program within the pipeline of OncoC4, a biotechnology company specializing in oncology therapeutics. As of early 2024, the company has not publicly disclosed the specific molecular target, modality, or chemical structure of the asset. The program is currently being evaluated for the treatment of solid tumors, aligning with OncoC4's broader focus on modulating immune responses and the tumor microenvironment through next-generation biologics and small molecules.

Targets

SIGLEC10 (Sialic acid–binding immunoglobulin-type lectin 10)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)

Beyond the preview

Go deeper on ONC-XXX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ONC-XXX.

Explore the full profile